LivaNova (NASDAQ:LIVN) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

LivaNova PLC (NASDAQ:LIVN) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $79.30 and traded as low as $74.64. LivaNova shares last traded at $75.07, with a volume of 528,515 shares trading hands.

Analysts Set New Price Targets

Several analysts have recently commented on LIVN shares. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Zacks Research cut shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Mizuho boosted their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, Needham & Company LLC increased their price target on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus target price of $84.12.

LivaNova Stock Performance

The firm’s 50 day moving average price is $79.30 and its 200-day moving average price is $74.54. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm has a market capitalization of $4.14 billion, a PE ratio of 22.21 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.05 EPS. On average, research analysts expect that LivaNova PLC will post 3.78 EPS for the current year.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director owned 4,434 shares in the company, valued at $345,896.34. This trade represents a 44.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,450 shares of company stock worth $591,839 in the last quarter. Insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Cim Investment Management Inc. acquired a new stake in shares of LivaNova in the second quarter worth approximately $248,000. Tidal Investments LLC purchased a new stake in shares of LivaNova during the second quarter worth $204,000. WINTON GROUP Ltd acquired a new stake in shares of LivaNova in the second quarter valued at about $4,824,000. Integrated Wealth Concepts LLC purchased a new position in shares of LivaNova in the second quarter worth about $119,000. Finally, Squarepoint Ops LLC acquired a new position in shares of LivaNova during the 2nd quarter worth approximately $1,418,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.